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Background
Despite the advent of typical and atypical antipsychotic
drugs, outcome of schizophrenia has remained unsatisfac-
tory. Alternative methods of treating schizophrenia are
being studied. Yoga treatment has been shown to have
anti-stress effect and is found to be useful in many psychi-
atric disorders. It has also been shown to be useful in
schizophrenia in open-label studies (Lukoff, 1986), but
randomized controlled studies are sparse.
Materials and methods
Sixty one patients (42 males; mean age: 31.6 ± 7.8 years)
with a DSM-IV diagnosis of schizophrenia attending out-
patient treatment at NIMHANS formed the sample. Most
were chronically ill (median duration of psychosis: 60
months), moderately ill (mean CGI severity score: 5.0 ±
0.84) and had no recent change in their medication. They
were randomized into Yoga and physical exercise (PE)
groups. Subjects in Yoga group were taught an integrated
Yoga programme developed for positive health (Nagar-
athna and Nagendra, 2004) and those in PE group were
taught stretching aerobic physical exercises. Subjects in
both groups underwent supervised training in Yoga or PE
for three weeks and practised the same at home for one
hour everyday for four months. Subjects were assessed
using the Positive and Negative Syndrome Scale (PANSS),
Hamilton Depression Rating Scale (HDRS), Social and
Adaptive Functioning Scale (SAFS), WHO Quality of Life
Scale (WHOQOL-BREF) and Clinical Global Impression-
Severity Scale (CGI-S) at baseline and after four months
by a trained rater. The rater was blind to the group status
of the subjects. Doses of antipsychotic medications were
not changed during the four months of trial. Data was
analysed using analysis of covariance with baseline scores
as covariates. Forty one (67%) completed the four month
follow-up. These did not differ from those who dropped
out on age, gender, duration of psychosis and baseline
PANSS, HDRS, SAFS, WHOQOL-BREF and CGI-S scores.
Results
The two groups did not differ on any of the baseline
parameters and antipsychotic dose. At the end of four
months the subjects in Yoga group had shown greater
improvement than those in the PE group in negative syn-
drome (F: 6.7; df: 1,38; p = 0.01), depression subscore (F:
8.5; df: 1,38; p < 0.01) and anergia subscore (F: 4.6; df:
1,38; p = 0.03) of PANSS; HDRS total score (F: 10.7; df:
1,38; p < 0.01); SAFS total score (F: 5.5; df: 1,38; p = 0.02)
and psychological quality of life (F: 7.8; df: 1,38; p < 0.01)
after controlling for respective baseline scores.
Discussion
Using a randomized single-blind research design this
study demonstrates that Yoga treatment is an useful add-
on treatment in schizophrenia. In particular, negative
symptoms, depression and psychological quality of life
tend to show differential improvement with Yoga treat-
ment.
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